Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34607583/
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS, NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis and cancer progression. The targeting...
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34625563/
Mouse models are critical in pre-clinical studies of cancer therapy, allowing dissection of mechanisms through chemical and genetic manipulations that are not feasible in the clinical setting. In studies of...
Comparative microsomal proteomics of a model lung cancer cell line NCI-H23 reveals distinct differences between molecular profiles of 3D and 2D cultured cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34611477/
Lung cancer is the leading cause of cancer-related deaths in the USA and worldwide. Yet, about 95% of new drug candidates validated in preclinical phase eventually fail in clinical trials....
Apoptosis-inducing activity of synthetic hydrocarbon-stapled peptides in H358 cancer cells expressing KRAS G12C - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34589388/
Lung cancers are the leading cause of cancer deaths worldwide and pose a grave threat to human life and health. Non-small cell lung cancer (NSCLC) is the most frequent malignancy...
-
KRAS Oncogene Connect4yrKey Points • Source: Acta Pharmaceutica Sinica B • Conclusion/Relevance: “Our study demonstrates that the stapled peptide 3 exhibits a stable α-helical structure with improved affinity and stability, strong resistance to proteolysis, Show More
Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34527319/
This study did not find a prognostic difference with sex, smoking history, age, or p.G12C mutation. The patients in this cohort with KRAS p.G12C had a numerically lower 12-month overall...